ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1825

Work Disability and Work Limitations in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Are Equal and Increase with Comorbidities

Chanseok Rhee1, Janet E. Pope2, Andrew E. Thompson3, Nicole G. H. Le Riche4, Gina Rohekar5 and Sherry Rohekar5, 1School of Medicine and Dentistry, Schulich School of Medicine and Dentisty, Western University, London, ON, Canada, 2Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, 3Rheumatology, St. Josephs Health Ctr, London, ON, Canada, 4Department of Medicine, St. Joseph's Hospital, London, ON, Canada, 5Rheumatology, St. Joseph's Hospital, London, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Disability, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: Few studies directly compare work disability (WD) and work productivity losses in different forms of inflammatory arthritis (IA) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Also, the effect of comorbidities on WD in IA has not been thoroughly examined.

Methods: WD was defined as the inability to work or early retirement due to arthritis. Relationships between the Work Limitations Questionnaire (WLQ) scores, HAQ, Patient Global Assessment (PGA) and Functional Comorbidity Index (FCI) were analyzed in patients seen serially in a rheumatology clinic via standardized forms.

Results: 846 responded (65% response rate with 332 RA, 88 PsA, 58 AS) and 289 had WLQ data as they were working (139 RA, 51 PsA, 35 AS). The mean age was 51.7 (SD 14.5), 74.3% female and 11.3 years (SD 11.3) of disease duration. WD due to arthritis was 22.8% (RA), 29.9% (PsA), and 27.6% (AS) (between groups p <0.35). WD was associated with HAQ, PGA, fatigue, pain and sleep score in all three IA conditions. The average loss of the productivity from WLQ was 4.72% for IA overall and 4.47%, 4.71% and 5.77% for RA, PsA and AS, respectively (no difference between groups, p=0.405). Using Pearson correlation, the WLQ score was significantly correlated with HAQ (0.59; p<0.000), fatigue (0.51; p<0.000), pain score (0.57; p<0.000), sleep score (0.63, p<0.000), and with increasing number of comorbid conditions for all three IA conditions (RA:0.30; p<0.01, PsA:0.30; p=0.03 and AS:0.53; p<0.01) but not disease duration and gender.

Conclusion: WD and productivity loss were not different in RA, PsA and AS. WLQ scores were associated with patient factors in all IAs. Comorbidities increased the likelihood of work productivity loss and WD in all forms of IA, but the correlation was particularly strong in AS.


Disclosure:

C. Rhee,
None;

J. E. Pope,

Actelion and Pfizer,

2,

Actelion and Pfizer,

5;

A. E. Thompson,
None;

N. G. H. Le Riche,
None;

G. Rohekar,
None;

S. Rohekar,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/work-disability-and-work-limitations-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis-are-equal-and-increase-with-comorbidities/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology